In addition, ongoing studies are evaluating the effect on bone turnover of novel anti-MM agents, including the proteasome inhibitor, ixazomib (NCT02499081), and the anti-CD38 antibody, daratumumab (NCT03475628). Here, CD38 is linked to Miyoshi myopathy.